Bristol-myers Squibb Compnay

Bayer Pharmaceuticals Corporation

Other

Smithkline Beecham Corporation

Bayer Corporation

James H Cook, Ii

F Christopher Zusi

John E Macor

Richard Eric Olson

Ivar M McDonald

Dalton King

Christiana I Iwuagwu

Nenghui Wang

Jeremy L Baryza

Ann-Marie Campbell

Gaetan H Ladouceur

Timothy G Lease

Matthew D Hill

Robert A Mate

Richard D Connell

Haiquan Fang

Derek B Lowe

Yamin Wang

Dhanapalan Nagarathnam

Jacques P Dumas

William Johnston Scott

Steven R Magnuson

Andreas Stolle

Donald J Wolanin

Soongyu Choi

Jill E Wood

David Gunn

Brian R Dixon

Peiying Liu

William H Bullock

Ning Miao Su

Richard H Kramss

Ning Qi

Catherine R Brennan

Philip D G Coish

Martin H Osterhout

Rex Denton

William R Schoen

Donald L Hertzog

Paul P Ehrlich

Anik&oacute; M Redman

William Carley

Ian McAlexander

Kimberley A Lentz

There are disclosed a series of quinuclidines having the Formula (I), which bind to the nicotinic &#x3b1;7 receptor and may be useful for the treatment of disorders of the central nervous system. 

Quinuclidine compounds as &#x3b1;-7 nicotinic acetylcholine receptor ligands

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands

The disclosure generally relates to compounds of the following formula, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs

The disclosure provides compounds of formula I, including Ia, Ib, Ic, or Id, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands

Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands

This invention related to novel sulfonamide substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.

Sulfonamide substituted chroman derivatives

Disclosed are substituted indoles, pharmaceutical compositions containing such indoles, and their use in treating or preventing PPAR-&ggr; mediated diseases or conditions, such as osteopenia, osteoporosis, cancer, diabetes and atherosclerosis.

Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-&ggr; binding agents

17-beta-hydroxysteroid dehydrogenase-II inhibitors

Substituted biphenyls having glucagon receptor antagonistic activity. Claimed compounds have the formula

Substituted biphenyls

Sulfonamide substituted chroman derivatives useful as beta 3

Growing community of inventors

East Hampton, CT, United States of America

James H Cook, Ii